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ABSTRACT 
Background: Breathlessness is common in patients with thoracic cancer but 
difficult to manage. The Incremental Shuttle Walking Test (ISWT) can help 
assess new treatments, but its repeatability has not been described in this 
group. 
Aim: To examine within and between day repeatability of the ISWT in this 
setting. 
Methods: Patients with incurable thoracic cancer were recruited from 
outpatient clinics at a University Hospital. Two ISWTs were completed one 
hour apart on two consecutive days, with the first test for familiarisation 
purposes only. Repeatability of distance walked was examined using Bland 
and Altman plots and assessed as the single determination (within subject) 
standard deviation of the difference between tests and its 95% range. 
Results: Forty-one patients participated and completed all tests. Mean (SD) 
distance walked was 333 (134), 349 (129) and 353 (130) m over the three 
tests, with the mean difference significantly different from zero between days 
(16 m, 95% CI 8 to 24 m, P=0.043) but not within days (5 m, 95% CI –2 to 12 
m, P=0.47). Within and between day single determination SD and 95% ranges 
were 30 (–31 to 91) m and 36 (–37 to 109) m respectively. 
Conclusions: These data help inform the design of studies making use of the 
ISWT and the interpretation of their findings. 
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1. Introduction 
Breathlessness on exertion is common in patients with incurable thoracic 
cancer, reducing exercise capacity and impacting negatively on levels of 
physical activity, independence and quality of life [1]. It remains difficult to 
manage, and the assessment of new treatments and approaches will be aided 
by reliable, objective measures of exercise capacity. The Incremental shuttle 
walking test (ISWT) is a field-based exercise test that is used to assess 
functional exercise capacity in a variety of settings [2, 3]. Although criterion 
and construct validity of the ISWT have been examined in patients with 
thoracic cancer, data on repeatability are lacking [4]; these would help inform 
clinical assessment protocols, intervention effect interpretation and study 
sample size requirements. We determined the within and between day 
repeatability of the distance walked in the ISWT, as part of a study examining 
factors limiting exercise capacity in this group [5]. 
2. Participants and methods 
Patients with incurable thoracic cancer and an Eastern Cooperative 
Oncology Group (ECOG) performance status of 0–2 reporting a reduction in 
their ability to undertake usual daily activities were recruited from outpatient 
clinics at Nottingham University Hospitals NHS Trust. Patients were excluded 
if they had received chemotherapy or radiotherapy within the last 4 weeks, or 
when their symptoms were amenable to a palliative intervention, e.g. drainage 
of a pleural effusion. Patients with chronic obstructive pulmonary disease 
(COPD) were included if this was not considered responsible for their decline 
in exercise capacity. All provided written informed consent and the study was 
approved by the Hospital Ethics Committee (EC99/45). 
The ISWT was undertaken twice on two consecutive days at the same 
time of day. This involved walking up and down a 10 m course marked by two 
cones at a speed dictated by pre-recorded bleeps on a tape cassette, which 
increased every minute until a symptom-limited maximum was reached (with 
breathlessness and leg fatigue rated using the modified Borg scale), and the 
total distance walked noted [2]. Patients received written instructions to avoid 
caffeinated drinks within one hour, large meals within two hours and excess 
alcohol the night before the test. They were advised to take their usual 
medication, wear comfortable shoes and to walk but not run. For each test, 
the patient wore a facemask, secured by a net cap, connected to a portable, 
lightweight, telemetric COSMED K4 b2 system (COSMED, Rome, Italy), 
fastened in a harness [6]. This permitted ventilation, oxygen uptake and heart 
rate to be measured [5]. On the first day, an initial ISWT was undertaken for 
familiarisation purposes as recommended by the developers [2]; this was 
followed, after 1h of rest, by Test 1. On the second day, Tests 2 and 3 were 
undertaken with a 1h rest period between. 
Within (Test 2 vs Test 3) and between day (Test 1 vs. Test 2) 
repeatability of distance walked was examined using Bland and Altman plots 
and assessed as the single determination (within subject) standard deviation 
of the difference between tests and its 95% range, corrected for a sample size 
<100, as described by Chinn [7]. The latter were also assessed for the 
difference between the familiarization test and Test 1 to determine its 
contribution. 
3. Results and discussion 
Forty-one eligible patients (21 male) were recruited and completed the study, 
with a mean (SD) age of 64 (8) years and a median (range) ECOG 
performance status of 1 (0–2). Twenty six had non-small cell lung cancer, 11 
mesothelioma and four small cell lung cancer. For full details see online 
supplementary table. All have since died with a median [IQR] survival of 39 
[24–61] weeks. Symptoms limiting exercise were breathlessness alone 
(n=28), breathlessness and leg fatigue equally (n=9), leg fatigue alone (n=3) 
and general fatigue (n=1). Based on the best distance walked, patients 
achieved a median [IQR] of 51 [41–66] % of the age-related mean distance 
walked by healthy volunteers [8]. 
 Figure. 1 shows Bland and Altman plots, and Table 1 repeatability 
outcomes of interest. The mean difference between tests was significantly 
different from zero between days (16 m, 95% CI 8 to 24 m, P=0.043) but not 
within days (5 m, 95% CI –2 to 12 m, P=0.47). The mean difference between 
the familiarization test and Test 1 was not significant (14 m, 95% CI -4 to 32 
m, P=0.14). 
To our knowledge, this is the first formal exploration of the repeatability of 
the ISWT in patients with incurable thoracic cancer, with data presented as 
recommended by Chinn [7]. Comparison with findings in other patient groups 
is limited because of differing methodology, e.g. repeatability described as an 
intraclass correlation coefficient, lack of the recommend familiarization test [2], 
and none used the COSMED K4 b2 [3]. Nonetheless, more favourable 
between day data than ours has been reported in patients with COPD, with a 
mean (95% CI) difference of –2 m (–22 to 18 m) between tests [2]. Wearing a 
mask may be a relevant factor, although only two patients reported feeling 
impeded by this. 
 Repeatability was poorer between day as compared to within day. 
Although not unexpected, because of the order in which the tests were done, 
a learning effect may have contributed to this difference; others have also 
reported first and second tests to differ significantly in patients with COPD, 
despite the use of a familiarization test [3]. Although the familiarization test 
was not significantly different from Test 1, its inclusion appears to improve 
subsequent repeatability. 
Strengths include a relatively large, well described group, 
representative of those most likely suitable for drug and non-drug treatments 
for breathlessness, including exercise. Our use of the COSMED K4 b2 permits 
additional data of relevance to be collected in future studies. A weakness is 
that between day testing was limited to consecutive days only. 
4. Conclusions 
We have described within and between day repeatability for the ISWT in 
patients with thoracic cancer. These data can help inform the design of 
studies making use of the ISWT and the interpretation of their findings. For 
example, although the minimum important difference of the ISWT has not 
been determined in thoracic cancer, applying our between day repeatability 
data to standard sample size calculations, suggests that to reliably detect the 
minimum important difference of 48 m reported in COPD [3], a within or 
between group comparison requires a sample size of 12 participants or 16 
participants per group respectively (power 80%, P=0.05). 
 
Declarations 
Conflicts of interest 
None. 
Funding 
This research was supported by funding from the University of 
Nottingham and League of Friends at Nottingham University Hospitals NHS 
Trust. 
Acknowledgements 
We would like to thank the patients who took part, Jacky Frisby and 
other colleagues who assisted with the original study, and Dr Tricia McKeever 
for statistical advice. 
 
References 
[1] Weingaertner V, Oek G, Scheve C, Gerdes V, Schwarz-Eywill M, Prenzel 
R et al. Breathlessness, functional status, distress, and palliative care 
needs over time in patients with advanced chronic obstructive pulmonary 
disease or lung cancer: a cohort study. Journal of pain and Symptom 
Management. 2014;48:569–81. 
[2] Singh S, Morgan MD, Scott S, Walters D, Hardman AE. Development of a 
shuttle walking test of disability in patients with chronic airways 
obstruction. Thorax 1992;47:1019–24. 
[3] Parreira VF, Janaudis-Ferreira T, Evans RA, Mathur S, Goldstein RS, 
Brooks D. Measurement properties of the incremental shuttle walk test. 
Chest 2014;145:1357–69. 
[4] Granger CL, Denehy L, Parry SM, Martin J, Dimitriadis, T, Sorohan M et 
al. Which field walking test should be used to assess functional exercise 
capacity in lung cancer? An observational study. BMC Pulmonary 
Medicine 2015;15:89. 
[5] England R, Maddocks M, Manderson C, Wilcock A. Factors influencing 
exercise performance in thoracic cancer. Respir Med 2012;106:294–9. 
[6] McLaughlin JE, King GA, Bassett DR, Ainsworth BE. Validation of the 
COSMED K4b2 portable metabolic system. Int J Sports Med 
2001;22:280–4. 
[7] Chinn S. Repeatability and method comparison. Thorax 1991;46:454–56. 
[8] Harrison SL, Greening NJ, Houchen-Wolloff L, Bankart J, Morgan MD, 
Steiner MC et al. Age-specific normal values for the incremental shuttle 
walking test in a healthy British population. J Cardiopulm Rehabil Prev 
2013;33:309–13. 
 
 
 
Table 1 Repeatability of the incremental shuttle walking test 
 Day 1 Day 2 
Outcome Familiarization Test 1 Test 2 Test 3 
Distance walked (metres)     
   Mean (SD) 320 (128) 333 (134) 349 (129) 353 (130) 
   Range 70–630 130–680 80–680 100–620 
Borg score (median, IQR) at discontinuation     
   Breathlessness 3, 2–4 3, 2–4 3, 2–4 3, 2–4 
   Leg fatigue 0.5, 0–2 0, 0–2 0, 0–2 0, 0–3 
Within day difference in distance walked     
   Mean (SD) difference 14 (58) 5 (43) 
   95% CI for mean difference –5 to 22 –2 to 12 
   Single determination (within subject) SD 42 30 
   Single determination 95% range –43 to 127 –31 to 91 
Between day difference in distance walked     
   Mean (SD) difference  16 (49)  
   95% CI for mean difference  8 to 24  
   Single determination (within subject) SD  36  
   Single determination 95% range  –37 to 109  
 
 
 
 
Figure 1.  Bland and Altman plots of mean distance and difference in distance 
walked between incremental shuttle walk tests repeated (a) within and (b) 
between days. Mean difference and 95% limits shown. 
 
  
Online supplementary table. Patient details. Mean (SD) or number of group 
unless specified otherwise. 
 
Age, years 64 (8) 
Gender, male:female 21:20 
Diagnosis 
    non-small cell/mesothelioma/small cell 
 
26/11/4 
ECOG performance status 
    0/1/2 
 
16/21/4 
Disease extent 
    local/advanced 
Metastases 
    lymph nodes/lung/bone/liver/adrenal 
 
21/20 
 
12/6/4/2/1 
Previous treatments 
    palliative chemotherapy 
    palliative radiotherapy 
    radical radiotherapy 
 
26 
10 
1 
Cigarette smoking status 
     ex smoker/current/never 
 
27/7/7 
Relevant co-morbidities 
    COPD 
    osteoarthritis 
    hypertension 
    diabetes 
    recent pulmonary embolism 
 
5 
3 
4 
4 
1 
Current medication 
     inhaled corticosteroid 
     inhaled bronchodilator 
     oral corticosteroid 
     diuretic 
     low molecular weight heparin 
 
5 
2 
2 
2 
1 
Anthropometry 
   height, cm 
   weight, kg 
   body mass index, kg.m2 
Inspiratory muscle strength 
    actual, cmH2O 
    % predicted 
Leg extensor power 
    watts 
    watts / kg 
 
169 (10) 
73 (14) 
25.4 (3.8) 
 
58 (32) 
63 (32) 
 
90 (43) 
1.23 (0.52) 
Spirometry 
    FEV1, L 
    FEV1 % predicted 
    FVC, L 
    FVC % predicted 
    FEV1:FVC% 
       <70% 
       ≥70% 
 
1.62 (0.59) 
60 (19) 
2.15 (0.73) 
64 (18) 
75 (11) 
25 
16 
 
